Walleye Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.47M Sell
148,500
-208,800
-58% -$6.72M 0.02% 867
2025
Q4
$11.2M Buy
357,300
+257,000
+256% +$6.33M 0.03% 588
2025
Q3
$2.03M Sell
100,300
-8,400
-8% -$148K 0.01% 1567
2025
Q2
$1.82M Sell
108,700
-22,000
-17% -$355K 0.01% 1589
2025
Q1
$2.01M Sell
130,700
-344,700
-73% -$6.16M 0.01% 1411
2024
Q4
$10.5M Buy
475,400
+109,200
+30% +$1.99M 0.03% 601
2024
Q3
$6.6M Buy
366,200
+223,300
+156% +$3.91M 0.01% 971
2024
Q2
$2.32M Buy
142,900
+73,000
+104% +$1.12M ﹤0.01% 1965
2024
Q1
$986K Buy
69,900
+45,500
+186% +$574K ﹤0.01% 2607
2023
Q4
$255K Buy
24,400
+13,900
+132% +$130K ﹤0.01% 3500
2023
Q3
$107K Buy
10,500
+4,400
+72% +$41K ﹤0.01% 3912
2023
Q2
$45.9K Buy
+6,100
New +$49.5K ﹤0.01% 3658
2022
Q4
Sell
-43,800
Closed -$353K 3632
2022
Q3
$353K Buy
+43,800
New +$387K 0.01% 1704
2020
Q1
Sell
-219,800
Closed -$2.15M 1637
2019
Q4
$2.15M Sell
219,800
-173,600
-44% -$1.55M 0.14% 179
2019
Q3
$2.71M Buy
393,400
+353,200
+879% +$2.71M 0.16% 149
2019
Q2
$371K Sell
40,200
-23,300
-37% -$281K 0.04% 639
2019
Q1
$996K Buy
+63,500
New +$1.12M 0.16% 165

Other funds holding TEVA

Walleye Capital's TEVA Position: Q1 2026 in Review

Walleye Capital opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2026: 2,309 shares worth $69.5K. The stake represents ﹤0.01% of the portfolio and ranks #3800 among its holdings. This is a return to the name: Walleye Capital previously reported a position in TEVA as recently as Q3 2025.

Walleye Capital first reported a position in TEVA in Q1 2019 and has held it in 13 quarters since. The position peaked at $22.2M in Q4 2024. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Walleye Capital held 2,309 shares of Teva Pharmaceuticals worth $69.5K as of Q1 2026.
  • Teva Pharmaceuticals was a new Walleye Capital position in Q1 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3800 holding.
  • Walleye Capital first reported a position in Teva Pharmaceuticals in Q1 2019 and has held it in 13 quarters since.
  • Walleye Capital's Teva Pharmaceuticals position peaked at $22.2M in Q4 2024.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.